USRE48635EActiveUtilityPatentIndex 59
ERK inhibitors
Est. expiryDec 22, 2034(~8.5 yrs left)· nominal 20-yr term from priority
Inventors:CORTEZ GUILLERMO SJOSEPH SAJANMCLEAN JOHNATHAN ALEXANDERMCMILLEN WILLIAM TRODRIGUEZ MICHAEL JOHNZHAO GAIYING
C07D 498/08A61P 35/00C07D 513/04C07D 495/04A61K 39/3955A61K 31/5377A61K 31/506C07K 16/2863A61K 31/519
59
PatentIndex Score
0
Cited by
7
References
42
Claims
Abstract
The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.
Claims
exact text as granted — not AI-modifiedWe claim:
1. A compound of the formula:
wherein:
R 1 is
R 2 and R 3 are methyl or R 2 and R 3 can be taken together to form cyclopropyl;
R 4 is hydrogen, methyl, chloro, fluoro, or trifluoromethyl; and
R 5 is
or a pharmaceutically acceptable salt thereof.
2. The compound or salt according to claim 1 wherein R 2 and R 3 are independently methyl.
3. The compound or salt according to claim 2 wherein R 4 is hydrogen.
4. The compound or salt according to claim 3 wherein R 1 is
5. The compound or salt according to claim 3 wherein R 5 is
6. The compound or salt according to claim 4 which is 6,6-dimethyl-2-{2-[(1-methyl-1H-pyrazol-5-yl)amino]pyrimidin-4-yl}-5-[2-(morpholin-4-yl)ethyl]-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one or a pharmaceutically acceptable salt thereof.
7. The compound according to claim 6 which is 6,6-dimethyl-2-{2-[(1-methyl-1H-pyrazol-5-yl)amino]pyrimidin-4-yl}-5-[2-(morpholin-4-yl)ethyl]-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one.
8. A pharmaceutical composition comprising a compound of the formula:
wherein:
R 1 is
R 2 and R 3 are methyl or R 2 and R 3 can be taken together to form cyclopropyl;
R 4 is hydrogen, methyl, chloro, fluoro, or trifluoromethyl; and
R 5 is
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.
9. The pharmaceutical composition according to claim 8 wherein R 2 and R 3 are independently methyl.
10. The pharmaceutical composition according to claim 9 wherein R 4 is hydrogen.
11. The pharmaceutical composition according to claim 10 wherein R 1 is
12. The pharmaceutical composition according to claim 10 wherein R 5 is
13. The A pharmaceutical composition according to claim 11 which is comprising 6,6-dimethyl-2-{2-[(1-methyl-1H-pyrazol-5-yl)amino]pyrimidin-4-yl}-5-[2-(morpholin-4-yl)ethyl]-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.
14. The pharmaceutical composition according to claim 13 which is comprising 6,6-dimethyl-2-{2-[(1-methyl-1H-pyrazol-5-yl)amino]pyrimidin-4-yl}-5-[2-(morpholin-4-yl)ethyl]-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one, and a pharmaceutically acceptable carrier, diluent, or excipient.
15. A method of treating cancer, comprising administering to a patient in need thereof, an effective amount of a compound of the formula:
wherein:
R 1 is
R 2 and R 3 are methyl or R 2 and R 3 can be taken together to form cyclopropyl;
R 4 is hydrogen, methyl, chloro, fluoro, or trifluoromethyl; and
R 5 is
or a pharmaceutically acceptable salt thereof, wherein the cancer is selected from the group consisting of melanoma, colorectal cancer, pancreatic cancer, and non-small cell lung cancer.
16. The method according to claim 15 wherein R 2 and R 3 are independently methyl.
17. The method according to claim 16 wherein R 4 is hydrogen.
18. The method according to claim 17 wherein R 1 is
19. The compound or salt method according to claim 17 wherein R 5 is
20. The compound or salt method according to claim 18 which wherein the compound is 6,6-dimethyl-2-{2-[(1-methyl-1H-pyrazol-5-yl)amino]pyrimidin-4-yl}-5-[2-(morpholin-4-yl)ethyl]-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one or a pharmaceutically acceptable salt thereof.
21. The compound method according to claim 20 which wherein the compound is 6,6-dimethyl-2-{2-[(1-methyl-1H-pyrazol-5-yl)amino]pyrimidin-4-yl}-5-[2-(morpholin-4-yl)ethyl]-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one.
22. The method according to claim 15 , wherein the cancer is colorectal cancer.
23. The method according to claim 16 , wherein the cancer is colorectal cancer.
24. The method according to claim 17 , wherein the cancer is colorectal cancer.
25. The method according to claim 18 , wherein the cancer is colorectal cancer.
26. The method according to claim 19 , wherein the cancer is colorectal cancer.
27. The method according to claim 20 , wherein the cancer is colorectal cancer.
28. The method according to claim 21 , wherein the cancer is colorectal cancer.
29. The method according to claim 15 , wherein the cancer is pancreatic cancer.
30. The method according to claim 16 , wherein the cancer is pancreatic cancer.
31. The method according to claim 17 , wherein the cancer is pancreatic cancer.
32. The method according to claim 18 , wherein the cancer is pancreatic cancer.
33. The method according to claim 19 , wherein the cancer is pancreatic cancer.
34. The method according to claim 20 , wherein the cancer is pancreatic cancer.
35. The method according to claim 21 , wherein the cancer is pancreatic cancer.
36. The method according to claim 15 , wherein the cancer is non-small cell lung cancer.
37. The method according to claim 16 , wherein the cancer is non-small cell lung cancer.
38. The method according to claim 17 , wherein the cancer is non-small cell lung cancer.
39. The method according to claim 18 , wherein the cancer is non-small cell lung cancer.
40. The method according to claim 19 , wherein the cancer is non-small cell lung cancer.
41. The method according to claim 20 , wherein the cancer is non-small cell lung cancer.
42. The method according to claim 21 , wherein the cancer is non-small cell lung cancer.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.